Welcome to our dedicated page for Cvrx SEC filings (Ticker: CVRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-trial data, device reimbursement hurdles, and highly technical risk factors make CVRx’s SEC filings a dense read for anyone tracking the Barostim neuromodulation platform. Finding how many implants shipped last quarter or which payers approved coverage can easily mean combing through hundreds of pages.
Stock Titan solves that problem. Our AI engine turns the CVRx annual report 10-K simplified into concise plain-English notes, flags every CVRx insider trading Form 4 transactions entry within minutes of EDGAR release, and even tags reimbursement language so you can focus on what moves the business. Whether you need the latest CVRx quarterly earnings report 10-Q filing, a quick look at CVRx Form 4 insider transactions real-time, or an alert when a new 8-K drops, the platform keeps you current without wading through PDFs.
Use cases are straightforward:
- Compare cash burn to implant growth with our CVRx earnings report filing analysis.
- Monitor surgeon-directors’ buys and sells via the CVRx executive stock transactions Form 4 feed.
- See how management’s pay aligns with trial milestones in the CVRx proxy statement executive compensation section.
- Get instant context on post-approval study disclosures through CVRx 8-K material events explained summaries.
From AI-powered summaries to real-time alerts, Stock Titan delivers CVRx SEC filings explained simply, so understanding CVRx SEC documents with AI becomes a five-minute task, not an afternoon project.
Brent Binkowski, Chief Operating Officer of CVRx (CVRX), acquired equity awards on 08/11/2025 that increase his direct stake in the company. He received 16,600 restricted stock units that vest 25% on each anniversary of the grant date, and was granted stock options for 74,900 shares with an exercise price of $7.51. The options vest 25% after one year and then 1/48th per month thereafter and have an expiration date listed as 08/10/2035. Following these transactions, the reporting person directly beneficially owns 16,600 shares and holds options for 74,900 shares.
FAQ
What is the current stock price of Cvrx (CVRX)?
What is the market cap of Cvrx (CVRX)?
